Shares of Aurinia Pharmaceuticals AUPH were unchanged after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 52.94% year over year to ($0.26), which missed the estimate of ($0.14).
Revenue of $29,000 unchanged by 0.00% year over year, which missed the estimate of $40,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 11, 2020
Time: 04:30 PM
ET Webcast URL: https://ir.auriniapharma.com/ir-calendar/detail/1330/second-quarter-2020-financial-results-conference-call
Recent Stock Performance
52-week high: $21.93
52-week low: $3.52
Price action over last quarter: down 18.71%
Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
